Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Stocks to Watch Right Now.
Iovance climbed to a new 52-week high on Friday, extending a three-day run, as investors gobbled up shares after an investment firm doubled its price target for its stock.
At intra-day trading, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) climbed to its highest price of $5.34 before paring gains to finish the session just up by 12.01 percent at $5.13 apiece.
Photo from Iovance Biotherapeutics website
In a market report, UBS raised its price target for the biopharmaceutical company to $4 from $2 previously, albeit remaining “neutral” for the stock.
On the other hand, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) maintained a more bullish rating from Wells Fargo, with the investment firm reaffirming its $14 price target and “buy” recommendation.
On Wednesday, March 11, investors will be closely watching out for business updates from Iovance Biotherapeutics Inc. (NASDAQ:IOVA) amid its participation in Barclays’ 28th Annual Global Healthcare Conference.
In recent news, the biopharmaceutical firm reported a 5 percent wider net loss last year at $390.98 million versus $372 million in 2024. Total revenues jumped by 60.6 percent to $263.5 million from $164.07 million year-on-year.
In the fourth quarter alone, net loss narrowed by 8 percent to $71.9 million from the $78.5 million in the same period a year earlier, while revenues increased by 17.6 percent to $86.7 million from $73.69 million year-on-year.
While we acknowledge the potential of IOVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
